# Ardelyx Inc. (ARDX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $3.78, market value $976 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Ardelyx Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 2.2×**. Each dollar of revenue is priced at 2.2×.
- **Price / book: 6.3×**. The shares trade at 6.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -1.8%** (5-yr avg -32.8%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -7.9%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -15.1%**. The company reported a net loss over the last twelve months.
- **Return on equity: -36.9%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -9.3%**. Return on all capital, debt included, is -9.3%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -11.1%**. Each dollar of assets produces -11.1% of profit.

## Growth
- **Revenue growth (1 yr): 22.1%** (3-yr 98.4%/yr, 5-yr 121.9%/yr). Revenue grew 22.1% over the last year, against 121.9% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -52.9%**. Earnings per share fell 52.9%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 1.21**. Debt is 1.21 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: net cash**. Ardelyx Inc. holds more cash than debt.
- **Altman Z-score: 2.76**. A Z-score of 2.76 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Ardelyx Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (10 analysts). 10 analysts cover Ardelyx Inc.; the consensus is strong_buy, with an average price target of $12.90 (+241% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -42.5%** (YTD -35.2%, 3-mo -32.0%). The shares are down 42.5% over twelve months including dividends.
- **From 52-week high: -55.0%** (2.7% above the low). Trading 55% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 32**. An RSI of 32 is neutral.
- **Beta (1 yr): 0.73** (volatility 62%). Beta of 0.73 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ARDX · Page: https://foliofundamentals.com/stocks/ardx

Not investment advice.